Connor, Clark & Lunn Investment Management (CC&L)
GLUE icon

Connor, Clark & Lunn Investment Management (CC&L)’s Monte Rosa Therapeutics GLUE Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14,655
Closed -$70.2K – 1450
2023
Q3 		$70.2K Buy
14,655
+2,197
+18% +$14.1K ﹤0.01% 1315
2023
Q2 		$85.3K Buy
+12,458
New +$80.6K ﹤0.01% 1250

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s GLUE Position: Q4 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Monte Rosa Therapeutics (GLUE) in Q4 2023, closing a stake of 14,655 shares — an estimated $70.2K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in GLUE in Q2 2023 and held it in 2 quarters. The position peaked at $85.3K in Q2 2023. 71 funds tracked by Wall St. Rank hold GLUE as of Q4 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Monte Rosa Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 14,655 Monte Rosa Therapeutics shares in Q4 2023, an estimated $70.2K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Monte Rosa Therapeutics in Q2 2023 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Monte Rosa Therapeutics position peaked at $85.3K in Q2 2023.
  • 71 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2023, filed 9 Feb 2024.